GSK plc has announced a breakthrough in the treatment of chronic hepatitis B, reporting a functional cure rate of 19% across two phase III trials of its antisense oligonucleotide bepirovirsen. Read More
Payoff for the November 2023 buyout of Immunogen Inc. came for Abbvie Inc. in the form of U.S. FDA clearance for the CD123-targeting antibody-drug conjugate Decnupaz (pivekimab sunirine) to treat adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an ultra-rare, aggressive and quick-killing hematologic malignancy. Read More
Abbott Laboratories received CE mark approval for two dual glucose and ketone sensing systems, bringing to the market sensors that could be transformational to the lives of people with diabetes at risk of diabetic ketoacidosis. Read More
Chinese biotech Longbio Pharma Co. Ltd. announced its IPO on the Hong Kong Stock Exchange to raise HK$1.362 billion (US$174 million) to progress its lead candidate, LP-003, a next-generation anti-IgE antibody. Read More
Landing on the right COVID-19 vaccine formulation for the coming season is becoming more complicated against a backdrop of low vaccination rates, young children with little to no immunization, declining surveillance data and a new SARS-COV-2 lineage slowly emerging. Read More
Recent findings are reshaping current understanding of the post-infection landscape of SARS-CoV-2. Although previous studies had already suggested that autoimmunity might underlie the persistent neurological symptoms seen in long COVID, researchers at Yale University and Mount Sinai now reinforce this hypothesis. SARS-CoV-2 infection appears to trigger an autoimmune mechanism that drives chronic pain, fatigue and cognitive impairment in some patients. Read More
Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for the targeted class of cancer therapeutics. Read More
With a historic WHO resolution adopted this week giving countries, for the first time, a mandate to address liver disease affecting 1.5 billion people worldwide, this momentum is strongly reflected at the ongoing European Association for the Study of the Liver 2026 congress in Barcelona. The mandate positions liver disease alongside cancer, cardiovascular disease and diabetes as a core global health priority. Read More
The BioWorld Drug Developers Index (BDDI) outpaced both the Nasdaq Biotechnology Index and the Dow Jones Industrial Average throughout the first four months of 2026. Starting the year in step with the broader indices, the BDDI pulled ahead steadily – climbing 4.41% year-to-date through January, 6.42% through February and 7.73% through March, before finishing April up 10.69% for the year. Read More
New hires and promotions in the biopharma and med-tech industries, including: Clearnote Health, Immunic, Indupro, Micron, Nocion, Nuvalent, Octave, Retension. Read More
Biopharma and med-tech companies raising money in public or private financings, including: Assembly, Bleednfire, Clearnote Health, Kardigan, Protuoso, Q32, Reprogram. Read More
Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Aavigen, Aim, Aptevo, Circio, Geovax, HCW, Mira, Miralogx, Niowave, Pacira, Traws, Wugen. Read More
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Astrazeneca, Atmo, Bridgebio, Cardiosense, Corcept, Dizal, Innocare, Nuvalent, Precigen, Senzime, Subtle, Vanda. Read More
